1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)
  4. Comunicacions a congressos (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/217315
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUgalde Altamirano, Jessica-
dc.contributor.authorRovira Juárez, Jordi-
dc.contributor.authorCampistol Plana, Josep M.-
dc.contributor.authorLozano, Miquel-
dc.contributor.authorCid Vidal, Joan-
dc.contributor.authorPiñeiro, Gastón Julio-
dc.contributor.authorRamirez, Maria Jose-
dc.contributor.authorCorral Velez, Vicente-
dc.contributor.authorRevuelta, Ignacio-
dc.contributor.authorRoca, Ramon-
dc.contributor.authorCalls, Jordi-
dc.contributor.authorTorregrosa Prats, José Vicente-
dc.date.accessioned2025-01-08T12:26:49Z-
dc.date.available2025-01-08T12:26:49Z-
dc.date.issued2024-05-01-
dc.identifier.issn1460-2385-
dc.identifier.urihttps://hdl.handle.net/2445/217315-
dc.descriptionComunicació/presentació a: 61st ERA Congress, The European Renal Association, Estocolm, 23-26 maig 2024-
dc.description.abstractFabry’s disease (FD) is a rare lysosomal disorder linked to the X chromosome due to a mutation in the gene encoding alpha-galactosidase A (alpha-Gal A). This mutation leads to a defect in the metabolism of glycosphingolipids, causing the progressive accumulation of globotriaacylceramide (GB3) or LysoGB3 in cells, tissues, and organs. In the treatment of FD, we have enzyme replacement therapy (ERT) with Agalsidase-alfa (Replagal®), Agalsidase-beta (Fabrazyme®), and chaperones (Migalastat®). However, there are limitations such as disease progression and morbimortality.-
dc.format.extent1 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherOxford University Press (OUP)-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1093/ndt/gfae069.264-
dc.relation.ispartofNephrology Dialysis Transplantation, 2024, vol. 39, sup. 1, p. i451-
dc.relation.urihttps://doi.org/10.1093/ndt/gfae069.264-
dc.rights(c) Ugalde Altamirano, Jessica et al., 2024-
dc.sourceComunicacions a congressos (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalaltia de Fabry-
dc.subject.classificationTerapèutica-
dc.subject.otherFabry's disease-
dc.subject.otherTherapeutics-
dc.titleTherapeutic apheresis in Fabry disease-
dc.typeinfo:eu-repo/semantics/conferenceObject-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.date.updated2024-12-13T10:13:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Comunicacions a congressos (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
gfae069-0264-3006.pdf94.69 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.